本文選題：子宮內(nèi)膜癌 + 人附睪上皮分泌蛋白��； 參考：《山東醫(yī)藥》2015年45期

【摘要】：目的觀察子宮內(nèi)膜癌患者血清人附睪上皮分泌蛋白4(HE4)、鱗狀細(xì)胞癌抗原(SCCAg)的水平變化,并探討其臨床意義。方法選取74例子宮內(nèi)膜癌患者(子宮內(nèi)膜癌組)、30例子宮內(nèi)膜非典型增生患者(增生組)及同期體檢健康的30例健康人群(對(duì)照組)作為研究對(duì)象,采用酶聯(lián)免疫吸附法檢測(cè)三組血清HE4、SCCAg,分析血清HE4、SCCAg與子宮內(nèi)膜癌患者盆腔淋巴結(jié)轉(zhuǎn)移及肌層浸潤(rùn)的關(guān)系。結(jié)果子宮內(nèi)膜癌組血清HE4、SCCAg水平顯著高于增生組、對(duì)照組(P均0.05),增生組與對(duì)照組血清HE4、SCCAg水平差異無(wú)統(tǒng)計(jì)學(xué)意義(P均0.05);在子宮內(nèi)膜癌患者中,FIGO分期Ⅰ期、Ⅱ期者血清HE4、SCCAg水平顯著低于Ⅲ期、Ⅳ期者(P均0.05),Ⅰ期與Ⅱ期、Ⅲ期與Ⅳ期者的血清HE4、SCCAg水平比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P均0.05)。22例發(fā)生淋巴結(jié)轉(zhuǎn)移子宮內(nèi)膜癌者血清HE4、SCCAg水平均顯著高于未發(fā)生淋巴結(jié)轉(zhuǎn)移者(P均0.05)。不同浸潤(rùn)深度的子宮內(nèi)膜癌患者血清HE4、SCCAg水平比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P均0.05)。結(jié)論子宮內(nèi)膜癌患者,尤其是發(fā)生淋巴結(jié)轉(zhuǎn)移者血清HE4、SCCAg水平明顯升高,檢測(cè)血清HE4、SCCAg水平有助于子宮內(nèi)膜癌的早期診斷及病情判斷。
[Abstract]:Objective to observe the changes of serum levels of human epididymal epithelial secretory protein 4 (HE4) and squamous cell carcinoma antigen (SCCAG) in patients with endometrial carcinoma and to explore its clinical significance. Methods 74 cases of endometrial carcinoma (endometrial carcinoma group, 30 cases of endometrial atypical hyperplasia group) and 30 cases of healthy people (control group) were studied. Enzyme linked immunosorbent assay (Elisa) was used to detect the levels of serum HE4, SCCAg and their relationship with pelvic lymph node metastasis and myometrium infiltration in patients with endometrial carcinoma. Results the level of serum HE4CCAg in endometrial carcinoma group was significantly higher than that in proliferative group (P < 0.05), but there was no significant difference between proliferative group and control group (P < 0.05), and there was no significant difference between proliferative group and control group (P < 0.05). The serum levels of HE4 and SCCAg in stage 鈪，

本文編號(hào)：2017453